Adrenoleukodystrophy Treatment Market Size Share Growth Opportunities and Forecast 2024

Adrenoleukodystrophy Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Adrenoleukodystrophy Treatment Market&nbsp;Size, Share &amp; Trends Analysis Report By Type, By Treatment, By End-user, By Region, And Segment Forecasts, 2024 &ndash; 2031</h2>

<h3>Market Overview</h3>

<blockquote>
The global adrenoleukodystrophy treatment market reached US$ 323.36 million in 2023 and is expected to reach US$ 673.03 million by 2031 growing with a CAGR of 9.6% during the forecast period 2024-2031.
</blockquote>

Adrenoleukodystrophy is a disease caused by a mutation in the ABCD1 gene that is located on the X chromosome. It is a neurodegenerative disease in which the protective myelin sheath covering the nerve fibers in the brain and spinal cord gradually deteriorates. This demyelination causes injury to the brain leading to the behavioral and neurological symptoms seen in the patients. The disease also affects the adrenal glands causing them not to produce enough steroid hormones.

The most common type of adrenoleukodystrophy is X-linked ALD caused by a genetic defect on the X chromosome. It mostly affects males more severely than females. The global adrenoleukodystrophy treatment market has witnessed significant growth in recent years due to the adoption of stem cell transplantation treatments. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only therapeutic approach to arrest cerebral demyelination of X‐linked adrenoleukodystrophy.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			9.6%
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Type Treatment and End Users
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/adrenoleukodystrophy-treatment-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers</h3>

Increasing Research &amp; Developments and Rising FDA Approvals of Drugs for Adrenoleukodystrophy Treatment&nbsp;

The demand for the global adrenoleukodystrophy treatment market is driven by multiple factors. One of the primary factors is the increasing research &amp; developments and rising FDA approvals of drugs for the treatment.

Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the white matter of the nervous system and the adrenal cortex. According to the National Organization for Rare Disorders in September 2022, the prevalence of ALD is estimated to be&nbsp;between 1 in 10,000 and 1 in 17,000 individuals&nbsp;in the general population.

Moreover, government initiatives and advanced research and developments in treating adrenoleukodystrophy help to drive this market growth. For instance, in August 2023, Orpheris announced that the drug Acetylcysteine zidrimer is under clinical development in Phase II for X-linked adrenoleukodystrophy (X-ALD).&nbsp;

In addition, key players in the industry strategies such as partnerships &amp; collaborations and product launches &amp; approvals would drive this market growth. For instance, in November 2022, Minoryx Therapeutics and Neuraxpharm collaborated on concluding the European regulatory process to obtain approval for leriglitazone for the treatment of adult male patients with X-ALD. Leriglitazone is the first approved treatment approved by the European Medicines Agency (EMA.

In May 2022, POXEL SA&nbsp; announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL065 and PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD).&nbsp;

Restraints

Factors such as the high cost of the treatment, side effects associated with stem cell transplants, a limited number of treatment options, and lack of awareness among people, are expected to hamper the market.

<h3>Segment Analysis</h3>

The global adrenoleukodystrophy treatment market is segmented based on type, treatment, end users, and region.

The childhood cerebral (cALD) segment accounted for approximately 38.5% of the global adrenoleukodystrophy treatment market share&nbsp;

The childhood cerebral (cALD) segment is expected to hold the largest market share over the forecast period. Childhood cerebral ALD (cALD )is the most devastating form of ALD. X-ALD (X-linked adrenoleukodystrophy) is an orphan neurodegenerative disease. The global incidence of X-ALD is approximately 6-8/100,000 live births. ALD patients, boys, and adult men, at any point in their lifetime, can develop cALD, characterized by demyelinating brain lesions that rapidly progress, leading to acute neurological decline and death.

Moreover, key players in the industry on ongoing advanced research &amp; developments and a rising number of clinical trials in the treatment of adrenoleukodystrophy would drive this segment growth. For instance, in April 2023, <a href="https://www.minoryx.com/">Minoryx Therapeutics</a>, announces 24-week interim results from NEXUS. This open-label registration-enabling clinical trial is assessing the safety and efficacy of lead candidate&nbsp;<a href="https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULBdGfJsTIDfVwJ7ge0xQNht0jcioqsxTPfCCj7HMUDNBzhir_rz8mv63stsmdFaf4dKiFuwLYCMXLwa1lGSCRfIHzDz4PVb3Cx-2FETyMJVRQPiC4L1sd1CQ5DA74U9L-2F3onfMxDRKqHpsM3WNTKlsz2nsRzAkoVT57Qg-2FCrlaYQLRuzULau3IxM0II6VNhB-2Bjni9JRw-2FPErwJja-2FHkLkIO4pn5-2FnP5CkAL70Y9X-2FsDKqaJ0yYca9WZ4Q-2Bs2xqXyKkdoQ5XrMF5QA1tLjeOKyAh8IOPAlvrXrbRRqbCjn3jQFZHw2UyjhCJjLOkPGfhM0uncz7d8ANWa6kgKY4EvBByX-2BV6ZLuFspUlmage9s3dC-2FW1Ow-2BK9yIC1DY1doeCtrXDMENtL1qB8bIet87UqpQu0q9e6oAbtzEALnSI3cuTeFiPwSpRw8T1WhsjXM2QorEgja0xiQ-3D-3D">leriglitazone</a>, a novel, brain-penetrant and selective PPAR gamma agonist, to treat pediatric patients with cerebral adrenoleukodystrophy (cALD) &ndash; a phenotype of X-linked adrenoleukodystrophy (X-ALD).&nbsp;

Similarly, in November 2023, Minoryx Therapeutics announced that the US Food and Drug Administration (FDA) approved its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (CALD). The CALYX protocol has received both FDA and central IRB approval.

<h3>Geographical Analysis</h3>

North America accounted for approximately 41.3% of the global adrenoleukodystrophy treatment market share&nbsp;

North America region is expected to hold the largest market share over the forecast period owing to factors such as increasing research and developments, drug approvals, and technological advancements in adrenoleukodystrophy treatment.

Moreover, the rising prevalence of ALD in the U.S. propels this market growth. According to the U.S. National Library of Medicine, in October 2022, the prevalence of ALD is 1 in 20,000 to 50,000 individuals worldwide.&nbsp; In the U.S., 1 in every 21,000 men is thought to be affected by ALD while 1 in 16,800 women are thought to be ALD carriers.&nbsp;&nbsp;

As per a newborn screening conducted in the state of New York, the incidence of ALD at birth was estimated to be 1 in 15,000. Among the 700,000 newborns screened in three years, 45 babies were diagnosed with ALD.

In addition, major players in the industry strategies such as FDA approvals and research &amp; development in the treatment of adrenoleukodystrophy would drive this market growth. For instance, in September 2022, Bluebird Bio received FDA accelerated approval for SKYSONA Gene Therapy for early, active cerebral adrenoleukodystrophy (CALD). This therapy slows down the progression of neurologic dysfunction in boys 4-17 years of age with early and active cerebral adrenoleukodystrophy (CALD).

Also,&nbsp; in January 2022, SwanBio Therapeutics announced that its Investigational New Drug (IND) application for its lead candidate SBT101 for the treatment of adrenomyeloneuropathy (AMN) is cleared by the U.S. Food and Drug Administration (FDA). SBT101 is the first AAV-based gene therapy in development specifically designed for people living with adrenomyeloneuropathy.&nbsp;

<h3>Market Segmentation</h3>

By Type

<ul>
	<li>Childhood Cerebral ALD</li>
	<li>Adrenomyeloneuropathy (AMN)</li>
	<li>Addison&#39;s Disease</li>
</ul>

By Treatment

<ul>
	<li>Stem Cell Transplant</li>
	<li>Corticosteroid Replacement Therapy</li>
	<li>Medications</li>
	<li>Gene Therapy</li>
	<li>Lorenzo&#39;s Oil</li>
	<li>Others</li>
</ul>

By End Users

<ul>
	<li>Hospitals</li>
	<li>Specialty Clinics</li>
	<li>Others</li>
</ul>

By Region

<ul>
	<li>North America
	<ul>
		<li>U.S.</li>
		<li>Canada</li>
		<li>Mexico</li>
	</ul>
	</li>
	<li>Europe
	<ul>
		<li>Germany</li>
		<li>U.K.</li>
		<li>France</li>
		<li>Italy</li>
		<li>Spain</li>
		<li>Rest of Europe</li>
	</ul>
	</li>
	<li>South America
	<ul>
		<li>Brazil</li>
		<li>Argentina</li>
		<li>Rest of South America</li>
	</ul>
	</li>
	<li>Asia-Pacific
	<ul>
		<li>China</li>
		<li>India</li>
		<li>Japan</li>
		<li>South Korea</li>
		<li>Rest of Asia-Pacific</li>
	</ul>
	</li>
	<li>Middle East and Africa</li>
</ul>

<h3>Competitive Landscape</h3>

The major global players in the adrenoleukodystrophy treatment market include Bluebird Bio Inc., Viking Therapeutics, Magenta Therapeutics, NeuroVia, Minoryx Therapeutics, Poxel S.A., Orpheris, SwanBio Therapeutics, Sperogenix Therapeutics, and Autobahn Therapeutics among others.

<h3>Key Developments</h3>

<ul>
	<li>In May 2024, Minoryx Therapeutics announced that the EMA&rsquo;s Committee for Medicinal Products for Human Use (CHMP) has recommended not to grant marketing authorization for NEZGLYAL (leriglitazone) as a treatment for cALD following the completion of the re-examination procedure.</li>
	<li>In February 2024, Neuraxpharm Group and Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system disorders, reaffirm their commitment on Rare Disease Day 2024 to find better treatments for patients suffering from a range of rare diseases, such as leukodystrophy, including X-linked adrenoleukodystrophy (X-ALD) and more specifically cerebral adrenoleukodystrophy (cALD).</li>
	<li>In June 2022, POXEL SA announced its participation at the ULF (United Leukodystrophy Foundation) Scientific Symposium and Family Conference on June at Illinois, USA by using PXL065, two proprietary promising candidates that are focused on the treatment of adrenoleukodystrophy (ALD) which is a rare and genetic disease in adults.</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global adrenoleukodystrophy treatment market segmentation based on the type, treatment, end users and region as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of global adrenoleukodystrophy treatment market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping available as excel consisting of key products of all the major players.</li>
</ul>

The global adrenoleukodystrophy treatment market report would provide approximately 62 tables, 55 figures, and 184 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Type&nbsp;</li>
		<li>Snippet by Treatment</li>
		<li>Snippet by End Users</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing Research &amp; Developments and Rising FDA Approvals of Drugs for Adrenoleukodystrophy Treatment&nbsp;</li>
				<li>The Increasing Cases of X-linked Recessive Conditions</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>High Cost of the Treatment</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&rsquo;s 5 Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Unmet Needs</li>
		<li>Regulatory Analysis</li>
		<li>DMI Opinion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Childhood Cerebral ALD*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Adrenomyeloneuropathy (AMN)</li>
		<li>Addison&#39;s disease</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Attractiveness Index, By Treatment</li>
		</ol>
		</li>
		<li>Stem Cell Transplant
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Corticosteroid Replacement Therapy</li>
		<li>Medications</li>
		<li>Gene Therapy</li>
		<li>Lorenzo&#39;s Oil</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End Users</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users</li>
			<li>Market Attractiveness Index, By End Users</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Specialty Clinics</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>&nbsp;Introduction</li>
			<li>&nbsp;Key Region-Specific Dynamics</li>
			<li>&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users</li>
			<li>&nbsp;Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
			<li>Germany
			<ol>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
			<li>China
			<ol>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>&nbsp;Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Product Benchmarking</li>
		<li>Company Share Analysis</li>
		<li>Key Developments and Strategies</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Bluebird Bio Inc.*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Viking Therapeutics</li>
		<li>Magenta Therapeutics</li>
		<li>NeuroVia</li>
		<li>Minoryx Therapeutics</li>
		<li>Poxel S.A.</li>
		<li>Orpheris</li>
		<li>SwanBio Therapeutics</li>
		<li>Sperogenix Therapeutics</li>
		<li>Autobahn Therapeutics&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Adrenoleukodystrophy Treatment Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Adrenoleukodystrophy Treatment Market Value, By Treatment, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Adrenoleukodystrophy Treatment Market Value, By End User, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Adrenoleukodystrophy Treatment Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Adrenoleukodystrophy Treatment Market Value, By Type, 2023, 2027 &amp; 2031 (US$ Million)

Table 6 Global Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Adrenoleukodystrophy Treatment Market Value, By Treatment, 2023, 2027 &amp; 2031 (US$ Million)

Table 8 Global Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Adrenoleukodystrophy Treatment Market Value, By End User, 2023, 2027 &amp; 2031 (US$ Million)

Table 10 Global Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Adrenoleukodystrophy Treatment Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 12 Global Adrenoleukodystrophy Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Adrenoleukodystrophy Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Adrenoleukodystrophy Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Adrenoleukodystrophy Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 26 South America Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 South America Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 28 South America Adrenoleukodystrophy Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Adrenoleukodystrophy Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Adrenoleukodystrophy Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Adrenoleukodystrophy Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Adrenoleukodystrophy Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Bluebird Bio Inc: Overview

Table 34 Bluebird Bio Inc: Product Portfolio

Table 35 Bluebird Bio Inc: Key Developments

Table 36 Viking Therapeutics: Overview

Table 37 Viking Therapeutics: Product Portfolio

Table 38 Viking Therapeutics: Key Developments

Table 39 Magenta Therapeutics: Overview

Table 40 Magenta Therapeutics: Product Portfolio

Table 41 Magenta Therapeutics: Key Developments

Table 42 NeuroVia: Overview

Table 43 NeuroVia: Product Portfolio

Table 44 NeuroVia: Key Developments

Table 45 Minoryx Therapeutics: Overview

Table 46 Minoryx Therapeutics: Product Portfolio

Table 47 Minoryx Therapeutics: Key Developments

Table 48 Poxel S.A.: Overview

Table 49 Poxel S.A.: Product Portfolio

Table 50 Poxel S.A.: Key Developments

Table 51 Orpheris: Overview

Table 52 Orpheris: Product Portfolio

Table 53 Orpheris: Key Developments

Table 54 SwanBio Therapeutics: Overview

Table 55 SwanBio Therapeutics: Product Portfolio

Table 56 SwanBio Therapeutics: Key Developments

Table 57 Sperogenix Therapeutics: Overview

Table 58 Sperogenix Therapeutics: Product Portfolio

Table 59 Sperogenix Therapeutics: Key Developments

Table 60 Autobahn Therapeutics: Overview

Table 61 Autobahn Therapeutics: Product Portfolio

Table 62 Autobahn Therapeutics: Key Developments

List of Figures

Figure 1 Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 3 Global Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 4 Global Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 5 Global Adrenoleukodystrophy Treatment Market Share, By Region, 2023 &amp; 2031 (%)

Figure 6 Global Adrenoleukodystrophy Treatment Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Childhood Cerebral ALD Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Adrenomyeloneuropathy (AMN) Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Addison&#39;s Disease Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Global Adrenoleukodystrophy Treatment Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 11 Stem Cell Transplant Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Corticosteroid Replacement Therapy Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 13 Medications Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Gene Therapy Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 15 Lorenzo&#39;s Oil Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 Others Treatment in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Global Adrenoleukodystrophy Treatment Market Y-o-Y Growth, By End User, 2023-2031 (%)

Figure 18 Hospitals End User in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 Specialty Clinics End User in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 20 Others End User in Global Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 Global Adrenoleukodystrophy Treatment Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 22 North America Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 North America Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 24 North America Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 25 North America Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 26 North America Adrenoleukodystrophy Treatment Market Share, By Country, 2023 &amp; 2031 (%)

Figure 27 Asia-Pacific Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 28 Asia-Pacific Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 29 Asia-Pacific Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 30 Asia-Pacific Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 31 Asia-Pacific Adrenoleukodystrophy Treatment Market Share, By Country, 2023 &amp; 2031 (%)

Figure 32 Europe Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 33 Europe Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 34 Europe Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 35 Europe Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 36 Europe Adrenoleukodystrophy Treatment Market Share, By Country, 2023 &amp; 2031 (%)

Figure 37 South America Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 38 South America Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 39 South America Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 40 South America Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 41 South America Adrenoleukodystrophy Treatment Market Share, By Country, 2023 &amp; 2031 (%)

Figure 42 Middle East and Africa Adrenoleukodystrophy Treatment Market Value, 2022-2031 (US$ Million)

Figure 43 Middle East and Africa Adrenoleukodystrophy Treatment Market Share, By Type, 2023 &amp; 2031 (%)

Figure 44 Middle East and Africa Adrenoleukodystrophy Treatment Market Share, By Treatment, 2023 &amp; 2031 (%)

Figure 45 Middle East and Africa Adrenoleukodystrophy Treatment Market Share, By End User, 2023 &amp; 2031 (%)

Figure 46 Bluebird Bio Inc: Financials

Figure 47 Viking Therapeutics: Financials

Figure 48 Magenta Therapeutics: Financials

Figure 49 NeuroVia: Financials

Figure 50 Minoryx Therapeutics: Financials

Figure 51 Poxel S.A.: Financials

Figure 52 Orpheris: Financials

Figure 53 SwanBio Therapeutics: Financials

Figure 54 Sperogenix Therapeutics: Financials

Figure 55 Autobahn Therapeutics: Financials

Adrenoleukodystrophy Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Soft Tissue Sarcoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 May 20

Starting from

Kaposi Sarcoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 July 25

Starting from

Radiotherapy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 07

Starting from